Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XXVII alpha 1 chain (COL27A1) is a member of the fibrillar collagen family and functions as a structural protein in the extracellular matrix of cartilage and developing bone[1][2][3][4]. It plays a crucial role during chondrogenesis and endochondral ossification, particularly in the calcification of cartilage and the transition of cartilage to bone[1][2][4]. The protein, produced as a preproprotein, includes a signal peptide, N-terminal and C-terminal propeptides, and a major triple-helical domain characteristic of fibrillar collagens[4]. Type XXVII collagen contributes to the proper organization of chondrocytes and extracellular matrix assembly, forming part of the structural framework into which bone later forms during skeletogenesis[1][2]. Mutations or disruptions in COL27A1 function can cause disorganization in the growth plate and are most notably associated with Steel syndrome, a congenital skeletal disorder[2][4]. There is currently no evidence that COL27A1 serves as a direct therapeutic target, nor are there known pharmacological modulators or biomarker applications in clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type XXVII alpha 1 chain (COL27A1).